<p><em>Nu-3 代表了一种新型的强效、快速作用的广谱抗微生物药物，称为双膦酸盐类</em> <em>®</em></p>
<p>, /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc.（纳斯达克：LABT）是一家临床阶段的生物技术公司，正在开发一种新型的强效、快速作用的广谱抗微生物药物，称为双膦酸盐类，今天宣布其主要化合物 Nu-3 的抗微生物耐药性（AMR）数据呈积极趋势，该化合物正作为局部给药治疗感染性糖尿病足溃疡（iDFU）进行开发。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2618352/Lakewood_Amedex_Biotherapeutics_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="400" height="265" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2618352/Lakewood_Amedex_Biotherapeutics_Logo.jpg"/></p>
<p>Nu-3 是 Lakewood-Amedex Biotherapeutics 发现的一类新型抗微生物化合物，称为双膦酸盐类，这些化合物也正在进行临床前研究，作为复杂性尿路感染（cUTI）和肺部感染的潜在治疗。双膦酸盐类化合物已在体外显示出通过 pH 和浓度依赖性破坏细菌细胞膜迅速杀死细菌的能力，通常在不到一分钟的暴露时间内即可实现这一效果。这种作用机制有可能减少抗生素耐药细菌株带来的威胁，包括耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素肠球菌（VRE）等。</p>
<p>在实验室研究中，使用 Nu-3 对 <em>E. coli</em> 和 MRSA 进行连续传代 21 天，实验结束时，Nu-3 对 <em>E. coli</em> 的最小抑菌浓度（MIC）略有增加，而对 MRSA 则保持不变。相比之下，环丙沙星对 <em>E. coli</em> 的 MIC 增加了超过 2000 倍，对 MRSA 增加了超过 600 倍。此外，当评估对已对环丙沙星产生耐药性的细菌时，Nu-3 维持了其原始的 MIC，这意味着没有发生交叉耐药。</p>
<p>“在旨在诱导耐药性的实验中，双膦酸盐类保持了其体外效力和效能，显示出极低的耐药性发展潜力，这为我们的 Nu-3 候选药物针对 iDFU 提供了巨大的潜力，更广泛地说，我们正在努力寻找抗微生物耐药性解决方案，这是我们社会面临的一项重大健康挑战，” Lakewood-Amedex Biotherapeutics 首席执行官 Kelvin Cooper 博士表示。“值得注意的是，AMR 数据支持我们对双膦酸盐类化合物机制的理解，我们相信它们可以对革兰氏阳性、革兰氏阴性和多重耐药生物体提供广谱活性，并将为许多现有抗微生物类提供显著优势。”</p>
<p>全球抗微生物耐药性危机每年直接导致约 127 万人死亡，并导致全球近 500 万人死亡。“耐药病原体是一个日益严重的威胁，已使许多现有抗生素失效，导致死亡率上升以及更高的医疗成本和更长的住院时间，” 首席医学官兼临床开发高级副总裁 Thomas Balzer 博士表示。“在全球约 8.3 亿糖尿病患者中，约三分之一的人在其一生中会发展为糖尿病足溃疡（DFU），其中约 50% 会感染，许多患者在其一生中经历多次感染事件。我们正在开发 Nu-3 以满足这一非常庞大且严重不足的治疗需求。”</p>
<p>约 15% 到 20% 的 iDFU 案例是由耐药病原体引起的，主要是 MRSA，这突显了在早期阶段需要快速有效的治疗，包括有效消除耐药病原体以防止疾病进展和潜在的毁灭性并发症，如截肢。对于糖尿病患者而言，感染，尤其是在未治疗的情况下，是截肢的风险因素，此外还有外周动脉疾病等病症的存在。DFU 并发症的经济负担显著，2018 年美国的护理成本估计为 800 亿美元， comparable to the cost of treating the five most expensive forms of cancer in total.</p>
<p><strong>关于 Lakewood-Amedex Biotherapeutics Inc.</strong> Lakewood-Amedex Biotherapeutics Inc.（纳斯达克：LABT）是一家临床阶段的生物技术公司，开发一种新型的快速作用、广谱抗微生物药物——双膦酸盐类——以治疗感染性疾病并减少抗生素耐药细菌株（包括 MRSA、VRE 等）带来的威胁。有关更多信息，请访问 https://lakewoodamedex.com。</p>
<p><strong>前瞻性声明</strong> 本新闻稿可能包含根据 1995 年《私人证券诉讼改革法》定义的前瞻性声明。通常，&#34;相信&#34;、&#34;期望&#34;、&#34;打算&#34;、&#34;估计&#34;、&#34;预期&#34;、&#34;项目&#34;、&#34;将&#34; 和类似表达识别前瞻性声明，这些声明通常不是历史性质的。然而，缺乏这些词或类似表达并不意味着该声明不是前瞻性的。所有涉及我们预期或预计将来发生的运营表现、事件或发展的声明均为前瞻性声明。管理层认为这些前瞻性声明在作出时是合理的。然而，应谨慎对待，不要对任何此类前瞻性声明过度依赖，因为这些声明仅在作出时有效。我们的公司没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。此外，前瞻性声明受到某些风险和不确定性的影响，这可能导致我们公司的实际结果与历史经验和我们当前的期望或预测有实质性差异。</p>
<p>依赖此类声明涉及风险、不确定性和假设。这些声明基于 Lakewood‐Amedex Biotherapeutics Inc.管理层截至本新闻稿日期的当前估计和假设，并且可能会受到不确定性和变化的影响。本新闻稿中所包含的所有声明仅在本新闻稿日期有效，Lakewood‐Amedex Biotherapeutics Inc.不承担公开更新任何前瞻性声明的义务。</p>
<p><strong>联系方式</strong> 投资者关系</p>
<p>Tiberend Strategic Advisors, Inc.</p>
<p>David Irish</p>
<p>(231) 632-0002</p>
<p>dirish@tiberend.com</p>
<p>媒体关系</p>
<p>Tiberend Strategic Advisors, Inc.</p>
<p>Casey McDonald</p>
<p>(646) 577-8520</p>
<p>cmcdonald@tiberend.com</p>
<p>来源：Lakewood-Amedex Biotherapeutics Inc.</p>

Atara生物治疗

SNSE

<p>Lakewood-Amedex Biotherapeutics Inc.（纳斯达克股票代码：LABT）宣布其主要候选药物 Nu-3 的抗微生物耐药性数据呈积极趋势，Nu-3 是一种用于感染性糖尿病足溃疡的新型抗微生物治疗。Nu-3 所属的双膦酸盐类（Bisphosphocin®）在对抗抗生素耐药细菌方面显示出潜力，即使在耐药性发展后仍保持疗效。全球抗微生物耐药（AMR）危机导致显著的死亡率和医疗成本，突显了像 Nu-3 这样的有效治疗的必要性。该公司旨在填补糖尿病足溃疡的关键治疗空白，这种病症影响了相当一部分糖尿病人群</p>

<p><em>Nu-3 represents a novel class of potent, fast-acting, broad-spectrum antimicrobials called Bisphosphocins</em> <em>®</em></p>
<div class="lb-trans"><p><em>Nu-3 代表了一种新型的强效、快速作用的广谱抗微生物药物，称为双膦酸盐类</em> <em>®</em></p>
</div><p>, /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT) a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced positive antimicrobial resistance (AMR) data for its lead compound, Nu-3, which is being developed as a topically delivered treatment for infected diabetic foot ulcers (iDFU).</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc.（纳斯达克：LABT）是一家临床阶段的生物技术公司，正在开发一种新型的强效、快速作用的广谱抗微生物药物，称为双膦酸盐类，今天宣布其主要化合物 Nu-3 的抗微生物耐药性（AMR）数据呈积极趋势，该化合物正作为局部给药治疗感染性糖尿病足溃疡（iDFU）进行开发。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2618352/Lakewood_Amedex_Biotherapeutics_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2618352/Lakewood_Amedex_Biotherapeutics_Logo.jpg"/></p>
<p>Nu-3 is one of a new class of antimicrobial compounds discovered by Lakewood-Amedex Biotherapeutics called the Bisphosphocin® class, which are also being explored in pre-clinical studies as potential treatments for complicated urinary tract infection (cUTI) and pulmonary infections. The Bisphosphocin® class of compounds have been shown <em>in vitro</em> to rapidly kill bacteria through a pH and concentration dependent destabilization of the bacterial cell membrane, typically achieving this effect in under one minute of exposure. This mechanism of action offers the potential to reduce the threat posed by antibiotic-resistant bacterial strains, including Methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), Vancomycin-resistant <em>Enterococci</em>(VRE), and others.</p>
<div class="lb-trans"><p>Nu-3 是 Lakewood-Amedex Biotherapeutics 发现的一类新型抗微生物化合物，称为双膦酸盐类，这些化合物也正在进行临床前研究，作为复杂性尿路感染（cUTI）和肺部感染的潜在治疗。双膦酸盐类化合物已在体外显示出通过 pH 和浓度依赖性破坏细菌细胞膜迅速杀死细菌的能力，通常在不到一分钟的暴露时间内即可实现这一效果。这种作用机制有可能减少抗生素耐药细菌株带来的威胁，包括耐甲氧西林金黄色葡萄球菌（MRSA）、耐万古霉素肠球菌（VRE）等。</p>
</div><p>In laboratory studies using a serial passage of <em>E. coli</em> and MRSA in the presence of Nu-3 for 21 days, Nu-3 showed slightly increased Minimum Inhibitory Concentration (MIC) at the end of the experiment for <em>E. coli</em> and were unchanged for MRSA. In contrast, the MIC for the ciprofloxacin control had increased over 2,000-fold for <em>E. coli</em> and over 600-fold for MRSA. In addition, Nu-3 maintained its original MIC when assessed against the bacteria that had developed resistance to Ciprofloxacin, which implies that cross-resistance did not occur.</p>
<div class="lb-trans"><p>在实验室研究中，使用 Nu-3 对 <em>E. coli</em> 和 MRSA 进行连续传代 21 天，实验结束时，Nu-3 对 <em>E. coli</em> 的最小抑菌浓度（MIC）略有增加，而对 MRSA 则保持不变。相比之下，环丙沙星对 <em>E. coli</em> 的 MIC 增加了超过 2000 倍，对 MRSA 增加了超过 600 倍。此外，当评估对已对环丙沙星产生耐药性的细菌时，Nu-3 维持了其原始的 MIC，这意味着没有发生交叉耐药。</p>
</div><p>&#34;In experiments designed to induce resistance, the Bisphosphocin class has maintained its <em>in vitro</em> efficacy and potency, demonstrating a very low potential for resistance development, which confers enormous potential for our Nu-3 candidate targeting iDFU, and more broadly, as we work towards solutions for antimicrobial resistance, a major health challenge for our society,&#34; said Kelvin Cooper, Ph.D., Chief Executive Officer at Lakewood-Amedex Biotherapeutics. &#34;Notably, the AMR data support our understanding of the mechanism of the Bisphosphocin® class of compounds, which we believe can provide a broad spectrum of activity against gram-positive, gram-negative, and multidrug-resistant organisms, and would provide a significant advantage over many existing antimicrobial classes.&#34;</p>
<div class="lb-trans"><p>“在旨在诱导耐药性的实验中，双膦酸盐类保持了其体外效力和效能，显示出极低的耐药性发展潜力，这为我们的 Nu-3 候选药物针对 iDFU 提供了巨大的潜力，更广泛地说，我们正在努力寻找抗微生物耐药性解决方案，这是我们社会面临的一项重大健康挑战，” Lakewood-Amedex Biotherapeutics 首席执行官 Kelvin Cooper 博士表示。“值得注意的是，AMR 数据支持我们对双膦酸盐类化合物机制的理解，我们相信它们可以对革兰氏阳性、革兰氏阴性和多重耐药生物体提供广谱活性，并将为许多现有抗微生物类提供显著优势。”</p>
</div><p>The global AMR crisis is directly responsible for approximately 1.27 million deaths annually and contributes to nearly 5 million deaths worldwide. &#34;Drug-resistant pathogens are a rising threat that have rendered many existing antibiotics ineffective, leading to increased mortality as well as higher healthcare costs and longer hospital stays,&#34; stated Thomas Balzer, MD, Ph.D., Chief Medical Officer and Senior Vice President, Clinical Development. &#34;Of the approximately 830 million people who suffer from diabetes globally, about one third will develop a DFU in their life, of which about 50% will become infected, with many patients experiencing multiple infection events through their lives. We are developing Nu-3 to meet this very large, critically underserved treatment need.&#34;</p>
<div class="lb-trans"><p>全球抗微生物耐药性危机每年直接导致约 127 万人死亡，并导致全球近 500 万人死亡。“耐药病原体是一个日益严重的威胁，已使许多现有抗生素失效，导致死亡率上升以及更高的医疗成本和更长的住院时间，” 首席医学官兼临床开发高级副总裁 Thomas Balzer 博士表示。“在全球约 8.3 亿糖尿病患者中，约三分之一的人在其一生中会发展为糖尿病足溃疡（DFU），其中约 50% 会感染，许多患者在其一生中经历多次感染事件。我们正在开发 Nu-3 以满足这一非常庞大且严重不足的治疗需求。”</p>
</div><p>About 15% to 20% of iDFU cases are caused by resistant pathogens, primarily MRSA underscoring the need for rapid and effective treatment in the early stage, including effective elimination of resistant pathogens to prevent disease progression and potentially devastating complications like amputations. For individual with diabetes, infections, especially when left untreated, are a risk factor for amputations, alongside the presence of conditions like peripheral arterial disease. The economic burden of DFU complications is significant, with the cost of care estimated at $80 billion in 2018 in the U.S., comparable to the cost of treating the five most expensive forms of cancer in total.</p>
<div class="lb-trans"><p>约 15% 到 20% 的 iDFU 案例是由耐药病原体引起的，主要是 MRSA，这突显了在早期阶段需要快速有效的治疗，包括有效消除耐药病原体以防止疾病进展和潜在的毁灭性并发症，如截肢。对于糖尿病患者而言，感染，尤其是在未治疗的情况下，是截肢的风险因素，此外还有外周动脉疾病等病症的存在。DFU 并发症的经济负担显著，2018 年美国的护理成本估计为 800 亿美元， comparable to the cost of treating the five most expensive forms of cancer in total.</p>
</div><p><strong>About Lakewood-Amedex Biotherapeutics Inc.</strong> Lakewood-AmedexBiotherapeutics Inc. (NASDAQ: LABT) is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials – the Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit https://lakewoodamedex.com.</p>
<div class="lb-trans"><p><strong>关于 Lakewood-Amedex Biotherapeutics Inc.</strong> Lakewood-Amedex Biotherapeutics Inc.（纳斯达克：LABT）是一家临床阶段的生物技术公司，开发一种新型的快速作用、广谱抗微生物药物——双膦酸盐类——以治疗感染性疾病并减少抗生素耐药细菌株（包括 MRSA、VRE 等）带来的威胁。有关更多信息，请访问 https://lakewoodamedex.com。</p>
</div><p><strong>Forward-Looking Statements</strong> This press release may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Generally, the words &#34;believe,&#34; &#34;expect,&#34; &#34;intsend,&#34; &#34;estimate,&#34; &#34;anticipate,&#34; &#34;project,&#34; &#34;will&#34; and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. Our Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause our Company's actual results to differ materially from historical experience and our present expectations or projections.</p>
<div class="lb-trans"><p><strong>前瞻性声明</strong> 本新闻稿可能包含根据 1995 年《私人证券诉讼改革法》定义的前瞻性声明。通常，&#34;相信&#34;、&#34;期望&#34;、&#34;打算&#34;、&#34;估计&#34;、&#34;预期&#34;、&#34;项目&#34;、&#34;将&#34; 和类似表达识别前瞻性声明，这些声明通常不是历史性质的。然而，缺乏这些词或类似表达并不意味着该声明不是前瞻性的。所有涉及我们预期或预计将来发生的运营表现、事件或发展的声明均为前瞻性声明。管理层认为这些前瞻性声明在作出时是合理的。然而，应谨慎对待，不要对任何此类前瞻性声明过度依赖，因为这些声明仅在作出时有效。我们的公司没有义务公开更新或修订任何前瞻性声明，无论是由于新信息、未来事件还是其他原因，除非法律要求。此外，前瞻性声明受到某些风险和不确定性的影响，这可能导致我们公司的实际结果与历史经验和我们当前的期望或预测有实质性差异。</p>
</div><p>Relying on such statements involves risk, uncertainty and assumptions. These statements are based on the current estimates and assumptions of the management of Lakewood‐Amedex Biotherapeutics Inc. as of the date of this press release and are subject to uncertainty and changes. All statements obtained in this press release are made only as of the date of this press release and Lakewood‐Amedex Biotherapeutics Inc. does not undertake any obligation to publicly update any forward‐looking statements.</p>
<div class="lb-trans"><p>依赖此类声明涉及风险、不确定性和假设。这些声明基于 Lakewood‐Amedex Biotherapeutics Inc.管理层截至本新闻稿日期的当前估计和假设，并且可能会受到不确定性和变化的影响。本新闻稿中所包含的所有声明仅在本新闻稿日期有效，Lakewood‐Amedex Biotherapeutics Inc.不承担公开更新任何前瞻性声明的义务。</p>
</div><p><strong>Contact</strong> Investor Relations</p>
<div class="lb-trans"><p><strong>联系方式</strong> 投资者关系</p>
</div><p>Tiberend Strategic Advisors, Inc.</p>
<div class="lb-trans"><p>Tiberend Strategic Advisors, Inc.</p>
</div><p>David Irish</p>
<div class="lb-trans"><p>David Irish</p>
</div><p>(231) 632-0002</p>
<div class="lb-trans"><p>(231) 632-0002</p>
</div><p>dirish@tiberend.com</p>
<div class="lb-trans"><p>dirish@tiberend.com</p>
</div><p>Media Relations</p>
<div class="lb-trans"><p>媒体关系</p>
</div><p>Tiberend Strategic Advisors, Inc.</p>
<div class="lb-trans"><p>Tiberend Strategic Advisors, Inc.</p>
</div><p>Casey McDonald</p>
<div class="lb-trans"><p>Casey McDonald</p>
</div><p>(646) 577-8520</p>
<div class="lb-trans"><p>(646) 577-8520</p>
</div><p>cmcdonald@tiberend.com</p>
<div class="lb-trans"><p>cmcdonald@tiberend.com</p>
</div><p>SOURCE Lakewood-Amedex Biotherapeutics Inc.</p>
<div class="lb-trans"><p>来源：Lakewood-Amedex Biotherapeutics Inc.</p>
</div>

Lakewood-Amedex Biotherapeutics Announces Positive Antimicrobial Resistance Data for Lead Candidate Targeting Infected Diabetic Foot Ulcers | LABT Stock News

StockTitan

Sensei Biotherapeutics

LakeShore Biopharma

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

Invesco Nasdaq Biotechnology ETF

标普生物技术 3 倍做多 - Direxion

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

Lakewood-Amedex 生物治疗公司宣布，其主要候选药物针对感染性糖尿病足溃疡的抗菌耐药性数据呈现积极结果 | LABT 股票新闻